UCLA Clinical Translational Science Institute
UCLA Clinical Translational Science Institute
批准号:
10401701
负责人:
Steven M. Dubinett
金额:
$627.15万
依托单位国家:
美国
项目类别:
财政年份:
2016
资助国家:
美国
项目状态:
已结题
起止时间:
2016-07-01 至 2022-05-31
关键词:
AddressAdvocateAgreementBeliefCaringCessation of lifeClinicalClinical ResearchClinical SciencesCollaborationsCommunitiesCountyDiabetes MellitusDiagnosisEnsureEntrepreneurshipFacultyGenomicsGoalsHealthHealth Services AccessibilityHealth systemHealthcareHeart DiseasesHeterogeneityInformaticsInfrastructureInservice TrainingInstitutesInstitutionInvestigationLaboratoriesLanguageLeadershipLife Cycle StagesLos AngelesMedical centerMedicineMethodologyMethodsMissionModelingPatientsPovertyProcessPublic HealthPublicationsResearchResearch MethodologyResearch PersonnelResearch PriorityScholarshipScienceSpecial PopulationSpeedStrokeTestingTraining ProgramsTraining and EducationTranslational ResearchTranslationsUnited StatesUniversitiesViolenceburden of illnessclinical careclinical data warehousecohortcomparativedata resourcedesigndisabilityeducation researchethnic minority populationexperiencehealth disparityimprovedinnovationinter-institutionalmultidisciplinarynovelprecision medicineprematureprogramsrecruitservice organizationsocialtooltranslational impact
中文摘要
整体
项目总结/摘要
加州大学洛杉矶分校临床和转化科学研究所是加州大学洛杉矶分校韦斯特伍德,雪松,
西奈医疗中心,查尔斯河。德鲁医学与科学大学和洛杉矶生物医学
Harbor-UCLA医学中心它的使命是将生物医学创新应用于最大的
洛杉矶的健康需求-最大的和最种族,社会和经济多样性之一
在美国的县。我们的目标是成为CTSA联盟的主要贡献者
加快科技成果转化,造福全国。CTSI有五个目标:(1)编写
翻译团队进行高质量的,多学科的团队科学;(2)参与利益相关者
社区在临床和转化研究和传播成功的合作模式;
(3)将特殊人群,特别是那些经历健康差异的人群纳入研究;(4)
改进方法和流程,以加快科学翻译,克服关键障碍,
支持多地点研究;(5)为业务和科学障碍提供信息学解决方案,
在UCLA CTSI和CTSA网络内推进高影响力的转化科学。我们的新型
基础设施包括:洛杉矶数据资源(LADR),一个来自
六个洛杉矶机构;其治理协议是CTSA ACT计划的模型;
创新和实施核心与洛杉矶县,一个实验室,测试方法,以改善
照顾每年在县卫生系统接受治疗的近70万人;精准医学计划
这构成了将基因组水平诊断引入转化研究和临床护理的基础设施
在我们的UCLA中心,多个CTSA和合作机构;一个培训计划,
在职培训经验中的创业原则,指导调查人员利用其
当他们把他们的发现带到产品中时,他们自己的发现。我们建议将我们的CTSI从一个高-
一个功能齐全的服务组织成为一个集成良好的研究加速器,将开发,展示和
传播新的解决方案,翻译的路障,以最终造福洛杉矶社区,
我们的地区和国家。
英文摘要
OVERALL
PROJECT SUMMARY/ABSTRACT
The UCLA Clinical and Translational Science Institute is a research partnership of UCLA-Westwood, Cedars-
Sinai Medical Center, Charles R. Drew University of Medicine and Science and the Los Angeles Biomedical
Institute at Harbor-UCLA Medical Center. Its mission is to bring biomedical innovations to bear on the greatest
health needs of Los Angeles—the largest and one of the most ethnically, socially and economically diverse
counties in the United States. In doing so, our goal is to become a leading contributor in the CTSA Consortium
and speed scientific translation to benefit the nation as a whole. The CTSI has five aims: (1) Prepare the
translational workforce to conduct high-quality, multidisciplinary team science; (2) Engage stakeholder
communities in clinical and translational research and disseminate successful models of collaboration;
(3) Integrate special populations, especially those experiencing health disparities, into research; (4)
Improve methods and processes to accelerate scientific translation, overcome key roadblocks and
support multisite research; (5) Provide informatics solutions to operational and scientific roadblocks to
advance high-impact translational science within the UCLA CTSI and the CTSA network. Our novel
infrastructure includes: The Los Angeles Data Resource (LADR), a federation of clinical data warehouses from
six Los Angeles institutions; its governance agreement serves as the model for the CTSA ACT initiative; an
Innovation and Implementation Core with Los Angeles County, a laboratory for testing approaches for improving
care for the nearly 700,000 people annually treated in the county health system; a Precision Medicine program
that forms the infrastructure to bring genomic-level diagnosis to translational investigation and clinical care
across our UCLA Hub, multiple CTSAs and partner institutions; a training program that integrates
entrepreneurship principles in on-the-job training experiences in which investigators are guided to utilize their
own findings as they bring their discoveries to products. We propose to transform our CTSI from a high-
functioning service organization into a well-integrated research accelerator that will develop, demonstrate and
disseminate novel solutions to translational roadblocks, to the ultimate benefit of the Los Angeles community,
our region and the nation.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Early detection of metastatic disease in US Veterans following surgery for early stage lung cancer
-
批准号:10426073
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2020
-
负责人:Steven M. Dubinett
-
依托单位:
Exosome-mediated mechanisms of metastatic disease in non-small cell lung cancer
-
批准号:10293525
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2020
-
负责人:Steven M. Dubinett
-
依托单位:
Exosome-mediated mechanisms of metastatic disease in non-small cell lung cancer
-
批准号:9784401
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2020
-
负责人:Steven M. Dubinett
-
依托单位:
Exosome-mediated mechanisms of metastatic disease in non-small cell lung cancer
-
批准号:10513810
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2020
-
负责人:Steven M. Dubinett
-
依托单位:
Novel Computation Methods for the Analysis of Cell-Free DNA Sequence Data
-
批准号:10238894
-
项目类别:
-
资助金额:$55.22万
-
财政年份:2019
-
负责人:Steven M. Dubinett
-
依托单位:
Novel Computation Methods for the Analysis of Cell-Free DNA Sequence Data
-
批准号:10004012
-
项目类别:
-
资助金额:$55.22万
-
财政年份:2019
-
负责人:Steven M. Dubinett
-
依托单位:
The Lung PCA: A Multi-Dimensional Atlas of Pulmonary Premalignancy
-
批准号:10203247
-
项目类别:
-
资助金额:$15.99万
-
财政年份:2018
-
负责人:Steven M. Dubinett
-
依托单位:
The Lung PCA: A Multi-Dimensional Atlas of Pulmonary Premalignancy
-
批准号:10441645
-
项目类别:
-
资助金额:$10.0万
-
财政年份:2018
-
负责人:Steven M. Dubinett
-
依托单位:
Molecular, Cellular, and Tissue Characterization Unit
-
批准号:9627277
-
项目类别:
-
资助金额:$110.1万
-
财政年份:2018
-
负责人:Steven M. Dubinett
-
依托单位:
ConProject-001
-
批准号:10311408
-
项目类别:
-
资助金额:$32.67万
-
财政年份:2016
-
负责人:Steven M. Dubinett
-
依托单位:
UCLA Clinical Translational Science Institute
-
批准号:10200543
-
项目类别:
-
资助金额:$23.45万
-
财政年份:2016
-
负责人:Steven M. Dubinett
-
依托单位:
UCLA Clinical Translational Science Institute
-
批准号:9261167
-
项目类别:
-
资助金额:$1478.8万
-
财政年份:2016
-
负责人:Steven M. Dubinett
-
依托单位:
Clinically Actionable Neoantigens in Non-Small Cell Lung Cancer
-
批准号:10058759
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2012
-
负责人:Steven M. Dubinett
-
依托单位:
Intratumoral genetic therapy for lung cancer
-
批准号:7934435
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2012
-
负责人:Steven M. Dubinett
-
依托单位:
Intratumoral genetic therapy for lung cancer
-
批准号:8461073
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2012
-
负责人:Steven M. Dubinett
-
依托单位:
Clinically Actionable Neoantigens in Non-Small Cell Lung Cancer
-
批准号:9348557
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2012
-
负责人:Steven M. Dubinett
-
依托单位:
Intratumoral genetic therapy for lung cancer
-
批准号:8698360
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2012
-
负责人:Steven M. Dubinett
-
依托单位:
Intratumoral genetic therapy for lung cancer
-
批准号:8967131
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2012
-
负责人:Steven M. Dubinett
-
依托单位:
UCLA Clinical and Translational Science Institute
-
批准号:8270466
-
项目类别:
-
资助金额:$81.24万
-
财政年份:2011
-
负责人:Steven M. Dubinett
-
依托单位:
UCLA Clinical and Translational Science Institute
-
批准号:8634157
-
项目类别:
-
资助金额:$77.26万
-
财政年份:2011
-
负责人:Steven M. Dubinett
-
依托单位:
海外基金